Pediatric Preclinical Testing Consortium: Research Programs (U01)

The summary for the Pediatric Preclinical Testing Consortium: Research Programs (U01) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Pediatric Preclinical Testing Consortium: Research Programs (U01): This Funding Opportunity Announcement (FOA) is for Research Programs for in vivo and in vitro testing of the activity of pediatric anticancer drug candidates. These Research Programs are the fundamental part of the Pediatric Preclinical Testing Consortium (PPTC) initiative, which also includes a PPTC Coordinating Center (supported under RFA-CA-14-019). The main goal for PPTC is to develop a rigorous preclinical testing system for pediatric anticancer drug candidates and to generate reliable data that can be used to inform new agent prioritization decisions. This FOA invites applications for drug testing Research Programs focused on specific tumor types that are particularly relevant to pediatric oncology. Each application must propose only one testing Research Program from the following four types:Type A: Research Program for leukemia in vivo testing;Type B: Research Program for tumors of central nervous system (CNS) in vivo testing; Type C: Research Program for other (non-CNS) solid tumors testing in vivo; and Type D: Research Program for in vitro testing.Applicants may propose Research Programs of more than one type but only through separate applications for each. Applicants proposing in vivo testing programs must be capable of quantitative assessment of tumor regression and time to event for 6 to 10 new agents (or combinations of agents) annually across relevant, well-characterized preclinical models. All applicants are expected to have substantial expertise regarding the biology and therapeutic opportunities for the tumor types that they propose to study. The PPTC Research Program Awardees will be required to collaborate closely with the PPTC Coordinating Center.

Federal Grant Title:	Pediatric Preclinical Testing Consortium: Research Programs (U01)
Federal Agency Name:	National Institutes of Health
Grant Categories:	Education Health
Type of Opportunity:	Discretionary
Funding Opportunity Number:	RFA-CA-14-018
Type of Funding:	Cooperative Agreement
CFDA Numbers:	93.395
CFDA Descriptions:	Cancer Treatment Research
Current Application Deadline:	Nov 13, 2014
Original Application Deadline:	Nov 13, 2014
Posted Date:	September 5th, 2014
Creation Date:	Sep 5, 2014
Archive Date:	Dec 14, 2014
Total Program Funding:
Maximum Federal Grant Award:	none
Minimum Federal Grant Award:	none
Expected Number of Awards:
Cost Sharing or Matching:	No

Applicants Eligible for this Grant: State governments
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
City or township governments
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
County governments
Native American tribal governments (Federally recognized)
Native American tribal organizations (other than Federally recognized tribal governments)
Public and State controlled institutions of higher education
Small businesses
Public housing authorities/Indian housing authorities
Private institutions of higher education
Others (see text field entitled "Additional Information on Eligibility" for clarification)
Special district governments
Independent school districts
For profit organizations other than small businesses
Additional Information on Eligibility: Other Eligible Applicants include the following:
Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Non-domestic (non-U.S.) Entities (Foreign Organizations); Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Link to Full Grant Announcement: http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-14-018.html
Grant Announcement Contact: NIH OER Webmaster [email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster

National Institutes of Health 301-496-3405
Similar Government Grants: • Specialized Programs of Research Excellence (SPOREs) in Cancer Health Disparities and Mino...; • Cancer Adoptive Cellular Therapy Network (Can-ACT) for Pediatric Cancers (UG3/UH3 Clinical...; • Single Source: Pediatric Early Phase Clinical Trials Network (PEP-CTN; UM1 Clinical Trial ...; • Assay development and screening for discovery of chemical probes, drugs or immunomodulator...; • Next Generation Chemistry Centers for Fusion Oncoproteins (UM1 Clinical Trial Not Allowed); • Breast and Prostate Cancer Data Quality and Patterns of Care Study; • Consortium Therapeutic Studies of Primary Central Nervous System Malignancies in Adults; • National Cooperative Drug Discovery Groups for Cancer
More Grants from the National Institutes of Health: • Using Neuromodulation to Characterize the Continuum of Pathophysiology Between Substance U...; • NIDCR Predoctoral to Postdoctoral Transition Award to Promote a Diverse Dental, Oral and C...; • Neuropathological Interactions Between COVID-19 and ADRD (R01 - Clinical Trial Not Allowed...; • Promoting Broad Participation in NIDCD's Extramural Workforce through Research Education E...; • Protective Strategies to Reduce Amyloid Related Imaging Abnormalities (ARIA) After Anti-Am...